Are Pain Polymorphisms Associated with the Risk and Phenotype of Post-COVID Pain in Previously Hospitalized COVID-19 Survivors?

Fernández‐de‐las‐Peñas, César; Giordano, Rocco; Dı́az-Gil, Gema; Gil-Crujera, Antonio; Gómez-Sánchez, Stella M.; Ambite-Quesada, Silvia; Arendt-Nielsen, Lars

doi:10.3390/genes13081336

Cited by 12 publications

(11 citation statements)

References 44 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All participants provided their written informed consent prior to their inclusion. The same sample of COVID-19 survivors exhibiting post-COVID pain also participated in a previous study on pain SNPs [ 29 ], but current data presented here are new and not previously published. This study was approved by the Institutional Ethics Committees of all institutions/hospitals involved (URJC0907202015920; HUFA 20/126; HSO25112020; HUIL/092-20).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors

Fernández‐de‐las‐Peñas

Arendt‐Nielsen

Dı́az-Gil

et al. 2022

Genes

Self Cite

View full text Add to dashboard Cite

The aim of the study was to identify the association between four selected COVID-19 polymorphisms of ACE2 and TMPRSS2 receptors genes with the presence of long-COVID symptomatology in COVID-19 survivors. These genes were selected as they associate with the entry of the SARS-CoV-2 virus into the cells, so polymorphisms could be important for the prognoses of long-COVID symptoms. Two hundred and ninety-three (n = 293, 49.5% female, mean age: 55.6 ± 12.9 years) individuals who had been previously hospitalized due to COVID-19 were included. Three potential genotypes of the following single nucleotide polymorphisms (SNPs) were obtained from non-stimulated saliva samples of participants: ACE2 (rs2285666), ACE2 (rs2074192), TMPRSS2 (rs12329760), TMPRSS2 (rs2070788). Participants were asked to self-report the presence of any post-COVID defined as a symptom that started no later than one month after SARS-CoV-2 acute infection and whether the symptom persisted at the time of the study. At the time of the study (mean: 17.8, SD: 5.2 months after hospital discharge), 87.7% patients reported at least one symptom. Fatigue (62.8%), pain (39.9%) or memory loss (32.1%) were the most prevalent post-COVID symptoms. Overall, no differences in long-COVID symptoms were dependent on ACE2 rs2285666, ACE2 rs2074192, TMPRSS2 rs12329760, or TMPRSS2 rs2070788 genotypes. The four SNPs assessed, albeit previously associated with COVID-19 severity, do not predispose for developing long-COVID symptoms in people who were previously hospitalized due to COVID-19 during the first wave of the pandemic.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Genotyping collection and management procedures had been previously published [ 29 ]. Briefly, unstimulated whole saliva samples were collected from each subject.…”

Section: Methodsmentioning

confidence: 99%

Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors

Fernández‐de‐las‐Peñas

Arendt‐Nielsen

Dı́az-Gil

et al. 2022

Genes

Self Cite

View full text Add to dashboard Cite

show abstract

“…As previously described [ 26 ], 293 (49.5% female, age: 55.6 ± 12.9 years) previously hospitalized COVID-19 survivors from a sample of 350 invited to participate fulfilled all inclusion criteria. Fifty-seven (16%) were excluded: (1) refuse to participate ( n = 30); (2) comorbid diagnosis of fibromyalgia ( n = 20); (3) pain from neurological origin ( n = 5); or (4) pregnancy ( n = 2).…”

Section: Resultsmentioning

confidence: 99%

“…The procedure of extraction was the same as a previous study [ 26 ]. Genomic DNA was extracted from 500 mL of saliva using a MagMAX™ DNA Multi-Sample Ultra 2.0 Kit (Thermo Fisher Scientific Inc, Hemel Hempstead, Hertfordshire, UK).…”

Section: Methodsmentioning

confidence: 99%

Post-COVID Pain Is Not Associated with Inflammatory Polymorphisms in People Who Had Been Hospitalized by COVID-19

Fernández‐de‐las‐Peñas

Giordano

Dı́az-Gil

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Our aim was to assess the association between four inflammatory polymorphisms with the development of post-COVID pain and to associate these polymorphisms with the clinical pain phenotype in individuals who had been hospitalized by COVID-19. Three potential genotypes of IL-6 (rs1800796), IL-10 (rs1800896), TNF-α (rs1800629), and IFITM3 (rs12252) single nucleotide polymorphisms (SNPs) were obtained from no-stimulated saliva samples from 293 (49.5% female, mean age: 55.6 ± 12.9 years) previously hospitalized COVID-19 survivors by polymerase chain reactions. Pain phenotyping consisted of the evaluation of pain features, sensitization-associated symptoms, anxiety levels, depressive levels, sleep quality, catastrophizing, and kinesiophobia levels in patients with post-COVID pain. Analyses were conducted to associate clinical features with genotypes. One hundred and seventeen (39.9%) patients experienced post-COVID pain 17.8 ± 5.2 months after hospital discharge. No significant differences in the distribution of the genotype variants of any SNPs were identified between COVID-19 survivors with and without post-COVID pain (all, p > 0.47). Similarly, the clinical pain phenotype was not significantly different between patients with and without post-COVID pain since no differences in any variable were observed for any SNPs. In conclusion, four SNPs associated with inflammatory and immune responses did not appear to be associated with post-COVID pain in previously hospitalized COVID-19 survivors. Further, neither of the SNPs were involved in the phenotyping features of post-COVID pain.

show abstract

“…With regard to cardiovascular medicine, it is desirable to know specific genetic risk factors for the development of myocarditis during COVID-19 or upon vaccination [112,[165][166][167][168][169][170][226][227][228][229][230][231][232], or for development of long COVID syndromes [191,[233][234][235][236][237][238][239]. Fortunately, SARS-CoV-2 is rather rarely causing severe myocarditis or cardiomyopathies [165][166][167][168][169][170].…”

Section: Cardiovascular Immunobiology Of Covid-19 and Long Covid Synd...mentioning

confidence: 99%

Innate Immunity in Cardiovascular Diseases – Identification of Novel Molecular Players and Targets

Poller¹,

Heidecker²,

Ammirati³

et al. 2022

Preprint

View full text Add to dashboard Cite

During the past few years unexpected developments have driven studies in the field of clinical immunology. One driver of immense impact was the outbreak of a pandemic caused by the novel virus SARS-CoV-2. Excellent recent reviews address diverse aspects of immunological re-search into cardiovascular diseases. Here, we specifically focus on selected studies taking ad-vantage of advanced state-of-the-art molecular genetic methods ranging from genome-wide epi/transcriptome mapping and variant scanning to optogenetics and chemogenetics. First, we discuss emerging clinical relevance of advanced diagnostics for cardiovascular diseases - includ-ing those associated with COVID-19 - with a focus on the role of inflammation in cardiomyopa-thies and arrhythmias. Second, we consider newly identified immunological interactions at or-gan and systems level which affect cardiovascular pathogenesis. Thus, studies into immune in-fluences arising from the intestinal system are moving towards therapeutic exploitation. Fur-ther, powerful new research tools have enabled novel insight into brain – immune system inter-actions at unprecedented resolution. This latter line of investigation emphasizes the strength of influence of emotional stress - acting through defined brain regions - upon viral and cardiovas-cular disorders. Several challenges need to be overcome before the full impact of these far-reaching new findings will hit the clinical arena.

show abstract

Are Pain Polymorphisms Associated with the Risk and Phenotype of Post-COVID Pain in Previously Hospitalized COVID-19 Survivors?

Cited by 12 publications

References 44 publications

Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors

Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors

Post-COVID Pain Is Not Associated with Inflammatory Polymorphisms in People Who Had Been Hospitalized by COVID-19

Innate Immunity in Cardiovascular Diseases – Identification of Novel Molecular Players and Targets

Contact Info

Product

Resources

About